CYDY
Price
$0.30
Change
+$0.05 (+20.00%)
Updated
Feb 21 closing price
Capitalization
367.12M
65 days until earnings call
RGLS
Price
$1.31
Change
+$0.04 (+3.15%)
Updated
Feb 21 closing price
Capitalization
85.81M
24 days until earnings call
Ad is loading...

CYDY vs RGLS

Header iconCYDY vs RGLS Comparison
Open Charts CYDY vs RGLSBanner chart's image
CytoDyn
Price$0.30
Change+$0.05 (+20.00%)
Volume$4.7M
Capitalization367.12M
Regulus Therapeutics
Price$1.31
Change+$0.04 (+3.15%)
Volume$300.63K
Capitalization85.81M
CYDY vs RGLS Comparison Chart
Loading...
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYDY vs. RGLS commentary
Feb 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYDY is a StrongBuy and RGLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 24, 2025
Stock price -- (CYDY: $0.30 vs. RGLS: $1.31)
Brand notoriety: CYDY and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYDY: 133% vs. RGLS: 55%
Market capitalization -- CYDY: $367.12M vs. RGLS: $85.81M
CYDY [@Biotechnology] is valued at $367.12M. RGLS’s [@Biotechnology] market capitalization is $85.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYDY’s FA Score shows that 1 FA rating(s) are green whileRGLS’s FA Score has 1 green FA rating(s).

  • CYDY’s FA Score: 1 green, 4 red.
  • RGLS’s FA Score: 1 green, 4 red.
According to our system of comparison, CYDY is a better buy in the long-term than RGLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYDY’s TA Score shows that 5 TA indicator(s) are bullish while RGLS’s TA Score has 4 bullish TA indicator(s).

  • CYDY’s TA Score: 5 bullish, 4 bearish.
  • RGLS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RGLS is a better buy in the short-term than CYDY.

Price Growth

CYDY (@Biotechnology) experienced а +37.55% price change this week, while RGLS (@Biotechnology) price change was +8.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

CYDY is expected to report earnings on Apr 30, 2025.

RGLS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYDY($367M) has a higher market cap than RGLS($85.8M). CYDY YTD gains are higher at: 172.470 vs. RGLS (-17.089). CYDY has higher annual earnings (EBITDA): -8.83M vs. RGLS (-41.03M). RGLS has more cash in the bank: 87.3M vs. CYDY (21.3M). RGLS has less debt than CYDY: RGLS (476K) vs CYDY (28.7M). CYDY (0) and RGLS (0) have equivalent revenues.
CYDYRGLSCYDY / RGLS
Capitalization367M85.8M428%
EBITDA-8.83M-41.03M22%
Gain YTD172.470-17.089-1,009%
P/E RatioN/AN/A-
Revenue00-
Total Cash21.3M87.3M24%
Total Debt28.7M476K6,029%
FUNDAMENTALS RATINGS
CYDY vs RGLS: Fundamental Ratings
CYDY
RGLS
OUTLOOK RATING
1..100
2411
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3561
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYDY's Valuation (3) in the null industry is in the same range as RGLS (22) in the Pharmaceuticals Other industry. This means that CYDY’s stock grew similarly to RGLS’s over the last 12 months.

CYDY's Profit vs Risk Rating (100) in the null industry is in the same range as RGLS (100) in the Pharmaceuticals Other industry. This means that CYDY’s stock grew similarly to RGLS’s over the last 12 months.

RGLS's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CYDY (100) in the null industry. This means that RGLS’s stock grew similarly to CYDY’s over the last 12 months.

CYDY's Price Growth Rating (35) in the null industry is in the same range as RGLS (61) in the Pharmaceuticals Other industry. This means that CYDY’s stock grew similarly to RGLS’s over the last 12 months.

CYDY's P/E Growth Rating (100) in the null industry is in the same range as RGLS (100) in the Pharmaceuticals Other industry. This means that CYDY’s stock grew similarly to RGLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYDYRGLS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL245.55-0.28
-0.11%
Apple
BTC.X96273.920000-303.835940
-0.31%
Bitcoin cryptocurrency
SPY599.94-10.44
-1.71%
SPDR® S&P 500® ETF Trust
GME26.42-0.62
-2.29%
GameStop Corp
TSLA337.80-16.60
-4.68%
Tesla

CYDY and

Correlation & Price change

A.I.dvisor tells us that CYDY and RGLS have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYDY and RGLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYDY
1D Price
Change %
CYDY100%
+20.06%
RGLS - CYDY
25%
Poorly correlated
+3.15%
TNXP - CYDY
22%
Poorly correlated
-5.17%
AGNPF - CYDY
21%
Poorly correlated
+8.86%
CLNN - CYDY
20%
Poorly correlated
-1.77%
GNNSF - CYDY
16%
Poorly correlated
+23.18%
More

RGLS and

Correlation & Price change

A.I.dvisor tells us that RGLS and NAUT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGLS and NAUT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
+3.15%
NAUT - RGLS
27%
Poorly correlated
-3.75%
IMNM - RGLS
26%
Poorly correlated
-5.84%
SPRY - RGLS
26%
Poorly correlated
-4.58%
SLNCF - RGLS
25%
Poorly correlated
N/A
FENC - RGLS
24%
Poorly correlated
+0.76%
More